![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | C07D 405/12 | (2006.01) |
(11) | Number of the document | 3181561 |
(13) | Kind of document | T |
(96) | European patent application number | 17154840.7 |
Date of filing the European patent application | 2011-03-25 | |
(97) | Date of publication of the European application | 2017-06-21 |
(45) | Date of publication and mention of the grant of the patent | 2020-05-20 |
(46) | Date of publication of the claims translation |
(30) | Number | Date | Country code |
317376 P | 2010-03-25 | US | |
319953 P | 2010-04-01 | US | |
321636 P | 2010-04-07 | US | |
321561 P | 2010-04-07 | US |
(72) |
Keshavarz-Shokri, Ali, US
Zhang, Beili, US
Alcacio, Tim Edward, US
Lee, Elaine Chungmin, US
Zhang, Yuegang, US
Krawiec, Mariusz, US
Nugent, William A., US
|
(73) |
Vertex Pharmaceuticals Incorporated,
50 Northern Avenue, Boston, MA 02210,
US
|
(54) | SYNTHETIC INTERMEDIATE OF (R)-1(2,2 -DIFLUOROBENZO[D][1,3]DIOXOL-5YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2YL)-1H-INDOL-5YL)CYCLOPROPANECARBOXAMIDE |
SYNTHETIC INTERMEDIATE OF (R)-1(2,2 -DIFLUOROBENZO[D][1,3]DIOXOL-5YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2YL)-1H-INDOL-5YL)CYCLOPROPANECARBOXAMIDE |